Citations

Showing 10 of 108162 citations.

Use of Vascular Endothelial Growth Factor-D As a Targeted Therapy in Lymphedema Treatment: A Comprehensive Literature Review
Forte, Antonio J. , Huayllani, María T. , Anastasiadis, Panos Z. , McLaughlin, Sarah A. , Boczar, Daniel , Forte, Antonio Jorge

Mayo Clinic

Lymphatic Research and Biology | March 19, 2021 | Volume: 20 | Issue: 1 | Pages: 3-6

10.1089/lrb.2020.0011 | PMID 33739868 Get It

Background: Lymphangiogenic growth factors, such as vascular endothelial growth factor (VEGF)-D, are subjects of interest in studies of targeted therapies in lymphedema treatment. Methods and Results: We conducted a systematic review assessing the use of VEGF-D as a targeted therapy in lymphedema treatment. We hypothesized that VEGF-D was a promising therapy to induce lymphangiogenesis. Our search yielded 90 studies in the literature, but only 4 articles fulfilled our study eligibility criteria, and they were all experimental studies using viral gene transfer. The majority of the studies were conducted on small animals (mice) and investigated the effects of VEGF-D on lymph node transfer. All authors agreed about VEGF-D's lymphangiogenic potential, but they noticed that VEGF-C induced a superior lymphangiogenesis, and one study noticed that VEGF-D induced seroma. Conclusions: The publications assessing the use of VEGF-D as a targeted therapy in lymphedema treatment were able to demonstrate its lymphangiogenic potential. Nonetheless, further studies are still necessary to investigate VEGF-D's efficacy and safety in lymphedema treatment on patients.
Outcomes on anti‐VEGFR‐2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma
Fonkoua, Lionel Aurelien Kankeu , Chakrabarti, Sakti , Starr, Jason S. , Liu, Alex J. , Nevala, Wendy K. , Maus, Rachel L.G., Bois, Melanie C. , Pitot, Henry C., Chandrasekharan, Chandrikha , Ross, Helen J. , Wu, Tsung‐Teh, Graham, Rondell P. , Weiss, Matthias , Foster, Nathan R. , Yoon, Harry H. , Fonkoua, Lionel Aurelien A Kankeu , Kasi, Pashtoon M, Maus, Rachel L, Graham, Rondell P , Chakrabarti, Sakti , Sonbol, Mohamad Bassam , Kasi, Pashtoon Murtaza , Villasboas, José C. , Markovic, Svetomir N. , Dong, Haidong

Mayo Clinic

International Journal of Cancer | March 19, 2021 | Volume: 149 | Issue: 2 | Pages: 378-386

10.1002/ijc.33559 | PMID 33739449 Get It

AbstractThrough our involvement in KEYNOTE‐059, we unexpectedly observed durable responses in two patients with metastatic gastroesophageal adenocarcinoma (mGEA) who received ramucirumab (anti‐VEGFR‐2)/paclitaxel after immune checkpoint inhibition (ICI). To assess the reproducibility of this observation, we piloted an approach to administer ramucirumab/paclitaxel after ICI in more patients, and explored changes in the immune microenvironment. Nineteen consecutive patients with mGEA received ICI followed by ramucirumab/paclitaxel. Most (95%) did not respond to ICI, yet after irRECIST‐defined progression on ICI, all patients experienced tumor size reduction on ramucirumab/paclitaxel. The objective response rate (ORR) and progression‐free survival (PFS) on ramucirumab/paclitaxel after ICI were higher than on the last chemotherapy before ICI in the same group of patients (ORR, 58.8% vs 11.8%; PFS 12.2 vs 3.0 months; respectively). Paired tumor biopsies examined by imaging mass cytometry showed a median 5.5‐fold (range 4‐121) lower frequency of immunosuppressive forkhead box P3+ regulatory T cells with relatively preserved CD8+ T cells, post‐treatment versus pre‐treatment (n = 5 pairs). We then compared the outcomes of these 19 patients with a separate group who received ramucirumab/paclitaxel without preceding ICI (n = 68). Median overall survival on ramucirumab/paclitaxel was longer with (vs without) immediately preceding ICI (14.8 vs 7.4 months) including after multivariate analysis, as was PFS. In our small clinical series, outcomes appeared improved on anti‐VEGFR‐2/paclitaxel treatment when preceded by ICI, in association with alterations in the immune microenvironment. However, further investigation is needed to determine the generalizability of these data. Prospective clinical trials to evaluate sequential treatment with ICI followed by anti‐VEGF(R)/taxane are underway.
Multimorbidity, ageing and mortality: normative data and cohort study in an American population
Rocca, Walter A. , Boyd, Cynthia M. , Chamberlain, Alanna M. , Grossardt, Brandon R. , Bobo, William V. , St Sauver, Jennifer L , Chamberlain, Alanna M , Sauver, Jennifer L. St.

Mayo Clinic

BMJ Open | March 19, 2021 | Volume: 11 | Issue: 3 | Pages: e042633

10.1136/bmjopen-2020-042633 | PMID 33741663 Get It

Objectives To describe the percentile distribution of multimorbidity across age by sex, race and ethnicity, and to demonstrate the utility of multimorbidity percentiles to predict mortality. Design Population-based descriptive study and cohort study. Setting Olmsted County, Minnesota (USA). Participants We used the medical records-linkage system of the Rochester Epidemiology Project (REP; http://www.rochesterproject.org ) to identify all residents of Olmsted County, Minnesota who reached one or more birthdays between 1 January 2005 and 31 December 2014 (10 years). Methods For each person, we obtained the count of chronic conditions (out of 20 conditions) present on each birthday by extracting all of the diagnostic codes received in the 5 years before the index birthday from the electronic indexes of the REP. To compare each person’s count to peers of same age, the counts were transformed into percentiles of the total population and displayed graphically across age by sex, race and ethnicity. In addition, quintiles 1, 2, 4 and 5 were compared with quintile 3 (reference) to predict the risk of death at 1 year, 5 years and through end of follow-up using time-to-event analyses. Follow-up was passive using the REP. Results We identified 238 010 persons who experienced a total of 1 458 094 birthdays during the study period (median of 6 birthdays per person; IQR 3–10). The percentiles of multimorbidity across age did not vary noticeably by sex, race or ethnicity. In general, there was an increased risk of mortality at 1 and 5 years for quintiles 4 and 5 of multimorbidity. The risk of mortality for quintile 5 was greater for younger age groups and for women. Conclusions The assignment of multimorbidity percentiles to persons in a population may be a simple and intuitive tool to assess relative health status, and to predict short-term mortality, especially in younger persons and in women.
Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas
Pol, Tymon , Lindbäck, Johan , Alexander, John H. , Caterina, Raffaele De , Eikelboom, JW, Ezekowitz, Michael D. , Granger, Christopher B. , Siegbahn, Agneta , Wallentin, Lars , Lindbäck, Johan , De Caterina, Raffaele , Granger, Christopher B , Hijazi, Ziad , Bahit, Maria Cecilia , Eikelboom, John W. , Gersh, Bernard J. , Hylek, Elaine M. , Lópes, Renato D.

Mayo Clinic

Open Heart | March 19, 2021 | Volume: 8 | Issue: 1 | Pages: e001471

10.1136/openhrt-2020-001471 | PMID 33741689 Get It

Objectives Growth differentiation factor 15 (GDF-15) is a biomarker independently associated with bleeding and death in anticoagulated patients with atrial fibrillation (AF). GDF-15 is also used as one component in the more precise biomarker-based ABC (age, biomarkers, clinical history)-AF-bleeding and ABC-AF-death risk scores. Data from large trials indicate a geographic variability in regard to overall outcomes, including bleeding and mortality risk. Our aim was to assess the consistency of the association between GDF-15, ABC-AF-bleeding score and ABC-AF-death score, with major bleeding and death, across world geographic regions. Methods Data were available from 14 767 patients with AF from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial and 8651 patients with AF from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial in this cohort study. GDF-15 was analysed from plasma samples obtained at randomisation. The geographical consistency of the associations between outcomes and GDF-15, ABC-AF-bleeding score and ABC-AF-death scores were assessed by Cox-regression models including interactions with predefined geographical region. Results GDF-15 and the ABC-AF-bleeding score were associated with major bleeding in both trials across regions (p<0.0001). Similarly, GDF-15 and the ABC-AF-death score were associated with all-cause mortality in both trials across regions (p<0.0001). Overall, the association between GDF-15, the ABC-AF-bleeding score and ABC-AF-death risk score with major bleeding and death was consistent across regions in both ARISTOTLE and the RE-LY trial cohorts. The ABC-AF-bleeding and ABC-AF-death risk scores were consistent regarding discriminative ability when comparing geographic regions in both trial cohorts. The C-indices ranged from 0.649 to 0.760 for the ABC-AF-bleeding and from 0.677 to 0.806 for the ABC-AF-death score by different geographic regions. Conclusions In patients with AF on anticoagulation, GDF-15 and the biomarker-based ABC-AF-bleeding and ABC-AF-death risk scores are consistently associated with respectively increased risk of major bleeding and death and have similar prognostic value across world geographic regions. Trial registration number ClinicalTrials.gov Registry NCT00412984 and NCT00262600.
Evaluation of premature ventricular contractions originating from periprosthetic aortic valve regions
Han, Jie , Lee, Justin Z. , Cha, Yong‐Mei

Mayo Clinic

Journal of Cardiovascular Electrophysiology | March 19, 2021 | Volume: 32 | Issue: 5 | Pages: 1519-1519

10.1111/jce.14990 | PMID 33738873 Get It

Harmonized outcome measures for use in degenerative lumbar spondylolisthesis patient registries and clinical practice
Devin, Clinton J. , Archer, Kristin R. , Bydon, Mohamad , Dinstein, Doron, Nerenz, David R. , Eakin, Guy S. , Shaffer, William O. , Washabaugh, Charles H., Gliklich, Richard E , Harbaugh, Robert E. , Leavy, Michelle B , Ghogawala, Zoher , Goertz, Christine , Lavelle, William Francis , Arnold, Paul M.

Mayo Clinic

Journal of Neurosurgery: Spine | March 19, 2021 | Volume: 34 | Issue: 6 | Pages: 888-896

10.3171/2020.9.spine20437 | PMID 33740766 Get It

OBJECTIVE The development of new treatment approaches for degenerative lumbar spondylolisthesis (DLS) has introduced many questions about comparative effectiveness and long-term outcomes. Patient registries collect robust, longitudinal data that could be combined or aggregated to form a national and potentially international research data infrastructure to address these and other research questions. However, linking data across registries is challenging because registries typically define and capture different outcome measures. Variation in outcome measures occurs in clinical practice and other types of research studies as well, limiting the utility of existing data sources for addressing new research questions. The purpose of this project was to develop a minimum set of patient- and clinician-relevant standardized outcome measures that are feasible for collection in DLS registries and clinical practice. METHODS Nineteen DLS registries, observational studies, and quality improvement efforts were invited to participate and submit outcome measures. A stakeholder panel was organized that included representatives from medical specialty societies, health systems, government agencies, payers, industries, health information technology organizations, and patient advocacy groups. The panel categorized the measures using the Agency for Healthcare Research and Quality’s Outcome Measures Framework (OMF), identified a minimum set of outcome measures, and developed standardized definitions through a consensus-based process. RESULTS The panel identified and harmonized 57 outcome measures into a minimum set of 10 core outcome measure areas and 6 supplemental outcome measure areas. The measures are organized into the OMF categories of survival, clinical response, events of interest, patient-reported outcomes, and resource utilization. CONCLUSIONS This effort identified a minimum set of standardized measures that are relevant to patients and clinicians and appropriate for use in DLS registries, other research efforts, and clinical practice. Collection of these measures across registries and clinical practice is an important step for building research data infrastructure, creating learning healthcare systems, and improving patient management and outcomes in DLS.
Resolution of Loculated Chylous Ascites Using Intraperitoneal Fibrinolytic Therapy
Oblizajek, Nicholas R. , Kamath, Patrick S. , Oblizajek, Nicholas R

Mayo Clinic

Hepatology | March 19, 2021 | Volume: 74 | Issue: 4 | Pages: 2293-2295

10.1002/hep.31816 | PMID 33738838 Get It

Image processing and machine learning for telehealth craniosynostosis screening in newborns
Ahn, Edward S. , Stoltz, Petronella, Martin, Jonathan E. , Bookland, Markus J.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | March 19, 2021 | Volume: 27 | Issue: 5 | Pages: 581-588

10.3171/2020.9.peds20605 | PMID 33740758 Get It

OBJECTIVE The authors sought to evaluate the accuracy of a novel telehealth-compatible diagnostic software system for identifying craniosynostosis within a newborn (< 1 year old) population. Agreement with gold standard craniometric diagnostics was also assessed. METHODS Cranial shape classification software accuracy was compared to that of blinded craniofacial specialists using a data set of open-source (n = 40) and retrospectively collected newborn orthogonal top-down cranial images, with or without additional facial views (n = 339), culled between April 1, 2008, and February 29, 2020. Based on image quality, midface visibility, and visibility of the cranial equator, 351 image sets were deemed acceptable. Accuracy, sensitivity, and specificity were calculated for the software versus specialist classification. Software agreement with optical craniometrics was assessed with intraclass correlation coefficients. RESULTS The cranial shape classification software had an accuracy of 93.3% (95% CI 86.8–98.8; p < 0.001), with a sensitivity of 92.0% and specificity of 94.3%. Intraclass correlation coefficients for measurements of the cephalic index and cranial vault asymmetry index compared to optical measurements were 0.95 (95% CI 0.84–0.98; p < 0.001) and 0.67 (95% CI 0.24–0.88; p = 0.003), respectively. CONCLUSIONS These results support the use of image processing–based neonatal cranial deformity classification software for remote screening of nonsyndromic craniosynostosis in a newborn population and as a substitute for optical scanner– or CT-based craniometrics. This work has implications that suggest the potential for the development of software for a mobile platform that would allow for screening by telemedicine or in a primary care setting.
Youth and parent report of sleep-based interventions and utilization of technology resources in the treatment of pediatric mood disorders
Leffler, Jarrod M. , Zelic, Kate J., Kruser, Amelia F, Lange, Hadley J, Lange, Hadley

Mayo Clinic

Clinical Child Psychology and Psychiatry | March 19, 2021 | Volume: 26 | Issue: 4 | Pages: 924-937

10.1177/13591045211000104 | PMID 33736503 Get It

Objectives: Mood disorders in youth are associated with social and academic impairment, and difficulties within the family system. Engagement in sleep hygiene, and family- and technology-based treatment models can address these impairments. The current study evaluates changes in functioning for youth who participated in a family-based partial hospitalization program (PHP) for mood disorders. Child and parent views of the importance and application of sleep hygiene and utilization of technology-based interventions were also evaluated. Methods: 474 youth diagnosed with a primary mood disorder and their caregivers participated in a family-based PHP that addressed the role of sleep hygiene, technology use for symptom management, and components of evidence-based treatments in ameliorating mood disorders. Participants were evaluated 1-, 3-, and 6-month following treatment. Results: Participants demonstrated improved functioning in social, home, and school domains. The majority of participants and parents found the sleep hygiene content and application important or very important as a component of treatment. Parents were significantly more likely than youth to be interested in using technology to access after care resources. Conclusions: Findings revealed significantly less impairment in functioning at follow-up. Parents and youth reported interest in sleep hygiene strategies as part of a comprehensive treatment for mood disorders as well as the use of technology-based resources to assist with treatment. Limitations include sample demographics and follow-up sample size.
Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C
Tse, Chung Sang , Yang, Ju Dong , Mousa, Omar Y. , Nelson, Kevin M., Pungpapong, Surakit , Aqel, Bashar , Vargas, Hugo E. , Dickson, Rolland C. , Watt, Kymberly D. , Roberts, Lewis R. , Leise, Michael D. , Keaveny, Andrew, Vargas, Hugo, Watt, Kymberly, Roberts, Lewis R , Tse, C S , Vargas, Hugo E , Pungpapong, Surakit , Yang, Ju Dong , Keaveny, Andrew P. , Aqel, Bashar A. , Gores, Gregory J.

Mayo Clinic

Transplantation Direct | March 18, 2021 | Volume: 7 | Issue: 1 | Pages: e635

10.1097/txd.0000000000001049 | PMID 33324740 Get It

Background: Direct-acting antivirals (DAA) are highly effective for the treatment of hepatitis C (HCV), although there are limited data on the safety and efficacy of DAA therapy in hepatitis C-positive individuals awaiting liver transplantation for hepatocellular carcinoma (HCC). Methods: We conducted a retrospective cohort study of HCV-positive patients who underwent liver transplantation for HCC at 3 liver transplant centers across the United States from 2014 to 2017 with follow-up to July 2018. Transplant recipients who received DAA before transplant were compared with those who did not (DAA naive) for posttransplant HCC recurrence rate, sustained virological response (SVR), allograft failure, and death using Kaplan-Meier analysis and Cox proportional hazard models. Results: A total of 171 HCV-HCC transplant recipients (99 pretransplant DAA; 72 DAA naive controls) were included, with a median follow-up of 24 months. The overall posttransplant HCC recurrence rate was 9% (15/171). Pretransplant DAA was not associated with HCC recurrence (5% versus 14%; P = 0.07), graft failure (7% versus 3%; P = 0.21), or death (12% versus 19%; P = 0.19) as compared with DAA naive patients. SVR rates were significantly lower (P < 0.01) with pretransplant DAA (75%, 39/52) than posttransplant DAA (97%, 59/61) therapies. Those who received pretransplant DAA and those who did not were not statistically different in age, gender, alpha fetal protein levels, model for end-stage liver disease scores, or transplant wait time. Conclusions: Pretransplant DAA for HCV was not associated with an increased risk of posttransplant HCC recurrence, though pretransplant DAA had lower efficacy than posttransplant DAA in HCV-HCC transplant recipients.